<DOC>
	<DOC>NCT01294410</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical therapy for ulcerative colitis</brief_summary>
	<brief_title>Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Clinical diagnosis of moderate to severe UC confirmed by endoscopic and histologic evidence Mayo score ≥6 with an endoscopic subscore of ≥2 Inadequate response and/or intolerance to one or more conventional therapy (i.e. oral aminosalicylates, immunosuppressants, corticosteroids, and/or TNF antagonist) Diagnosis of Crohn's Disease or Indeterminate Colitis Diagnosis of UC that is limited to the rectum Evidence of fulminant colitis, toxic megacolon, or bowel perforation Current need for a colostomy or ileostomy Previous total or subtotal colectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>